Roche Recalls Cymevene Powder for Infusion Due to Sterility Concerns
F. Hoffmann-LaRoche Ltd. is recalling Cymevene 500 mg Powder for Infusion due to container closure issues that compromise sterility assurance. No product was distributed in the USA.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classified this as an FDA Class II recall. Per the rubric, FDA Class II recalls involving significant injury/property-damage reports or structural defects are rated Severe (4). While no specific injuries are reported in the text, the loss of sterility assurance in an infusion product is a significant safety hazard.
Plain-English summary
F. Hoffmann-LaRoche Ltd. is recalling Cymevene 500 mg Powder for Infusion (ganciclovir), 50 mg/mL, 10 mL vials. The recall is due to container closure issues with the bulk batch that result in a lack of assurance of sterility.
The affected product includes bulk lot N0019 and finished product lots N0019B01 through N0019B12. The source text states that no product was distributed in the USA. Bulk product was distributed to Switzerland, with further distribution in Europe, Scandinavia, and Korea.
Consumers and healthcare providers in the United States are not affected by this recall. Those in affected regions should contact their healthcare provider or the manufacturer for instructions on how to handle the recalled product.
The recalled product
- Product
- Cymevene 500 mg Powder for Infusion, (ganciclovir), 50 mg/mL ganciclovir (reconstructed), Rx only, 10 mL vials, Roche Products Limited, Welwyn Garden City, AL7 1TW, United Kingdom
- Manufacturer
- F. Hoffmann-LaRoche Ltd.
- Category
- Drug — Antiviral
- Affected units
- 42,010
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- bulk lot N0019
Distribution
Distribution scope not specified by the agency.
Related recalls
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29